Acumen Pharmaceuticals Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
61
- Stock Symbol
-
ABOS
- Share Price
-
$0.21
- (As of Friday Closing)
Acumen Pharmaceuticals General Information
Description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Contact Information
Website
www.acumenpharm.comCorporate Office
- 1210-1220 Washington Street
- Suite 210
- Newton, MA 02465
- United States
Corporate Office
- 1210-1220 Washington Street
- Suite 210
- Newton, MA 02465
- United States
Acumen Pharmaceuticals Timeline
Acumen Pharmaceuticals Stock Performance
As of 13-Nov-2026, Acumen Pharmaceuticals’s stock price is $0.21. Its current market cap is $15.5M with 72.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.21 | $0.22 | $0.19 - $3.60 | $15.5M | 72.3M | 2.53M | -$1.55 |
Acumen Pharmaceuticals Financials Summary
As of 30-Sep-2026, Acumen Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 81,993 | 32,037 | (68,538) | 6,944 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (103,838) | (124,374) | (112,400) | (62,397) |
| Net Income | (103,962) | (121,335) | (102,329) | (52,371) |
| Total Assets | 85,565 | 122,833 | 238,992 | 310,125 |
| Total Debt | 26,311 | 31,311 | 28,732 | 28,487 |
Acumen Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Acumen Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Acumen Pharmaceuticals Comparisons
Industry
Financing
Details
Acumen Pharmaceuticals Competitors (21)
One of Acumen Pharmaceuticals’s 21 competitors is Alzinova, a Corporation company based in Gothenburg, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alzinova | Corporation | Gothenburg, Sweden | ||||
| ProMIS Neurosciences | Corporation | Toronto, Canada | ||||
| Prothena | Corporation | Dublin, Ireland | ||||
| LeonaBio | Formerly VC-backed | Bothell, WA | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA |
Acumen Pharmaceuticals Patents
Acumen Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026164979-A1 | Anti-oligomeric amyloid beta antibody variant and methods of use thereof | Pending | 28-Jan-2025 | ||
| AU-2013355359-A1 | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 | Active | 04-Dec-2012 | ||
| AU-2013355359-B2 | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 | Active | 04-Dec-2012 | ||
| CA-2891627-A1 | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 | Active | 04-Dec-2012 | ||
| CA-2891627-C | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 | Active | 04-Dec-2012 | A61K39/3955 |
Acumen Pharmaceuticals Signals
Acumen Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Acumen Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.94 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Acumen Pharmaceuticals FAQs
-
When was Acumen Pharmaceuticals founded?
Acumen Pharmaceuticals was founded in 1996.
-
Where is Acumen Pharmaceuticals headquartered?
Acumen Pharmaceuticals is headquartered in Newton, MA.
-
What is the size of Acumen Pharmaceuticals?
Acumen Pharmaceuticals has 61 total employees.
-
What industry is Acumen Pharmaceuticals in?
Acumen Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Acumen Pharmaceuticals a private or public company?
Acumen Pharmaceuticals is a Public company.
-
What is Acumen Pharmaceuticals’s stock symbol?
The ticker symbol for Acumen Pharmaceuticals is ABOS.
-
What is the current stock price of Acumen Pharmaceuticals?
As of 13-Nov-2026 the stock price of Acumen Pharmaceuticals is $0.21.
-
What is the current market cap of Acumen Pharmaceuticals?
The current market capitalization of Acumen Pharmaceuticals is $15.5M.
-
Who are Acumen Pharmaceuticals’s competitors?
Alzinova, ProMIS Neurosciences, Prothena, LeonaBio, and Denali Therapeutics are some of the 21 competitors of Acumen Pharmaceuticals.
-
What is Acumen Pharmaceuticals’s annual earnings per share (EPS)?
Acumen Pharmaceuticals’s EPS for 12 months was -$1.55.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process